BioCryst Pharmaceuticals, Inc.

NASDAQ:BCRX

Biotechnology

Healthcare
$7.30 +1.02%

+$0.09 today

Market cap
$1.88B
Beta
0.56
P/E (TTM)
-4.8
EPS (TTM)
-$1.89
52W Low $6.00High $10.32

Volume 2.95M

Average 4.85M

BCRX Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

BioCryst Pharmaceuticals, Inc.NASDAQ: BCRX

Accounts Payables · Q2 FY2026 · quarter ended Jun 2026

Accounts payables outflow shrinks to $0

Q2 FY2026 accounts payables was $0, compared with $45.01M a year earlier. Trailing-twelve-month accounts payables was -$458K.

Context

  • Accounts payables amounted to 6.6% of revenue in FY2025, down 7.2 pp from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts payables holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$114.5K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0+100.0% QoQ
Last fiscal yearDec 2025
$57.8M+192.7% YoY
LTMJun 2026
-$458K-90.0% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+192.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
57.8M USD
Year-over-year change
+192.7%
4-year CAGR
+10.0%

Accounts Payables vs competitors

How BCRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -90.0% is the lowest of 3, against a peer median of +142.3%.
  • Accounts payables amounts to 0.0% of revenue for BCRX, versus a peer median of 3.3%.
BCRX Competitors
Accounts Payables for BCRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PHVSPharvaris N.V.LTM Sep 2026€4.81M EUR———
VIRVir Biotechnology, Inc.LTM Mar 2026$2.19M USD+169.7%+84.4%3.3%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$2.06M USD+115.0%——
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$458K USD-90.0%—0.0%
Peer median (excluding BCRX) —+142.3%+84.4%3.3%

Competitors are the stored peer set for BCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(184.06M)(247.12M)(226.54M)(88.88M)263.86M
Depreciation & Amortization777K1.44M1.66M1.25M1.39M
Deferred Income Tax00000
Stock-Based Compensation34.64M44.7M55.62M65.41M85.07M
Change in Working Capital8.12M(58.95M)(32.4M)(87.28M)(56.9M)
Accounts Receivables(20.82M)(21.47M)(6.1M)(22.7M)(36.81M)
Inventory(8.77M)(12.42M)(1.45M)(4.16M)(1.64M)
Accounts Payables39.41M(22.36M)(16.81M)(62.38M)57.8M
Other Working Capital(1.7M)(2.69M)(8.05M)1.96M(76.26M)
Other Non-Cash Items(1.64M)98.07M106.53M57.48M36.46M
Operating Cash Flow(142.16M)(161.85M)(95.14M)(52.02M)329.88M
Capital Expenditures(2.39M)(1.35M)(2.17M)(1.12M)(2.47M)
Acquisitions (Net)0000(6.18M)
Purchases of Investments(10.01M)(244.28M)(514.41M)(266.76M)(262.24M)
Sales of Investments28.2M117.4M385.08M320.48M256.65M
Other Investing Activities0000550K
Investing Cash Flow15.8M(128.24M)(131.5M)52.59M(13.69M)
Debt Repayment293.87M73.07M58.38M(1.7M)(332.77M)
Common Stock Issued50.06M190K342K34K9.17M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities15.73M14.77M(26.24M)(4.09M)(8.85M)
Financing Cash Flow359.67M88.03M32.49M(5.76M)(332.44M)
Effect of Forex Changes71K566K362K(936K)(87.07M)
Net Change in Cash233.39M(201.5M)(193.79M)(6.12M)(103.32M)
Free Cash Flow(144.54M)(163.2M)(97.31M)(53.14M)327.41M

BioCryst Pharmaceuticals, Inc.

NASDAQ:BCRX

Intrinsic Alpha fair value

Locked

Current Price

$7.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.